Latest news

• AZ gets EMA green light for severe asthma drug Fasenra

  AstraZeneca has picked up an approval in the EU for its interleukin-5 inhibitor Fasenra in severe asthma, mirroring its US approval in this indication last November. ... Prospects for IL-13 inhibitor tralokinumab look terminal after three failed

• AZ prices severe asthma drug Fasenra below competition

  The US FDA has approved AstraZeneca’s interleukin-5 inhibitor Fasenra for severe asthma, setting up a fight in the market with rival drugs from GlaxoSmithKline and Teva. ... Prospects for IL-13 inhibitor tralokinumab look rocky after two failed

• AZ severe asthma drug benralizumab backed by CHMP

  AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe

• Setback for AZ as tralokinumab flunks asthma trial

  Tralokinumab is an inhibitor of interleukin-13 (IL-13), while benralizumab works by blocking the activity of IL-5. ... The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13

• Sanofi, Regeneron claim EU approval for eczema drug Dupixent

  Dupixent (dupilumab) is an interleukin-4 (IL-4) and IL-13 inhibitor that can be administered by a patient every other week via a subcutaneous injection after an initial loading dose, ... Some analysts said the data fell short of expectations however -